Extensive studies have found that a single nucleotide polymorphism (SNP) +61 G/A (rs4444903) in the EGF gene is associated with the susceptibility of glioma, however, the results have been controversial.
Overall, there was a significant association between EGFrs4444903 polymorphism and glioma</span> risk in all four genetic models (the allele model: OR=1.25, 95 % CI 1.15-1.37, P<0.001; the codominant model: OR=1.65, 95 % CI 1.36-1.99, P<0.001; the dominant model: OR=1.27, 95 % CI 1.12-1.44, P<0.001; the recessive model: OR=1.48, 95 % CI 1.25-1.75, P<0.001).
Previous studies showed that the EGF +61G/A polymorphism (rs4444903) may lead to an alteration in EGF production and/or activity, which can result in individual susceptibility to glioma.
In the NAT2 polymorphism at nucleotide position 857G/A, the G allele and the GG genotype were the most prevalent forms in both the glioma and normal samples.